Any feedback?
Literature summary for 5.3.99.2 extracted from
- Pharmacokinetics of recombinant human lipocalin-type prostaglandin D synthase/beta-trace in canine (2008), Neurosci. Res., 61, 289-293.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | study on the pharmacokinetics of recombinant human lipocalin-type prostaglandin-D synthase in canines. After an intravenous bolus injection, the serum concentration decreases biexponentially with a half-life of the terminal line phase of 0.77 h. L-PGDS is distributed mainly in the blood. Only 10.3% of the administered enzyme is excreted to the urine, suggesting that L-PGDS is actively degraded within the body | Homo sapiens |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
lipocalin-type prostaglandin D synthase. Isoform is identical to beta-trace, a major protein in human cerebrospinal fluid, and acts as both a PGD2-producing enzyme and as an extracellular transporter for lipophilic ligands | - |
Source Tissue
| Source Tissue | Comment | Organism | Textmining |
|---|
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
